- Home
- CCTG vs MYNZ Comparison
CCTG vs MYNZ Comparison
Compare CCTG & MYNZ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CCTG | MYNZ |
|---|---|---|
| Founded | 1993 | 2021 |
| Country | Hong Kong | Germany |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0M | 5.4M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CCTG | MYNZ |
|---|---|---|
| Price | $0.60 | $0.74 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 105.0K | ★ 274.2K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.08 | $0.55 |
| 52 Week High | $2.61 | $5.69 |
Technical Indicators
Market Signals| Indicator | CCTG | MYNZ |
|---|---|---|
| Relative Strength Index (RSI) | 52.38 | 40.78 |
| Support Level | $0.58 | $0.60 |
| Resistance Level | $1.13 | $1.71 |
| Average True Range (ATR) | 0.07 | 0.11 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 17.81 | 44.48 |
Price Performance
Historical ComparisonAbout CCTG CCSC Technology International Holdings Limited
CCSC Technology International Holdings Ltd along with its subsidiaries is involved in the sale, design, and manufacturing of interconnect products, including connectors, cables, and wire harnesses. Its products include customized interconnect products, including connectors, cables, and harnesses that are used for a range of applications in a diversified set of industries, including industrial, automotive, robotics, medical equipment, computer, network and telecommunication, and consumer products. Geographically, the company generates maximum revenue from the sale of its products in Europe and the rest from the Americas, Asia, and Others.
About MYNZ Mainz Biomed N.V.
Mainz Biomed NV develops market-ready molecular genetic diagnostic solutions for life-threatening conditions. The company's flagship product is ColoAlert, is an accurate, non-invasive and easy-to-use, early-detection diagnostic test for colorectal cancer based on real-time Polymerase Chain Reaction-based (PCR) multiplex detection of molecular-genetic biomarkers in stool samples. The company operates in one operating segment, genetic diagnostic testing.